HDAC9 and T-cell non-Hodgkin lymphoma: However, the enhanced antiproliferative effect of the 3ClQuin-SAHA in T-cell lymphoma cells may not be easily attributed to an additive or even synergistic effect of the HDAC-and EGFR-inhibiting pharmacophores of the compound, because additional FACS analyses on the expression of EGFR receptors in the T-cell lymphoma cell lines revealed that none of the four cell lines expressed EGFR receptors on their cell surface (Supplementary Figure S1).